Celerion (United States)

Recent papers from Celerion (United States)

1. Liquid Compared to Solid Oral Formulations of the Thyroid Hormone Receptor Agonist Elunetirom Under Fasted and Fed Conditions in Healthy ParticipantsClinical and Translational Science · 2026
2. Phase 1 Evaluation of Pharmacokinetic Drug-Drug Interactions Between Enlicitide and Multiple Concomitant MedicationsAtherosclerosis · 2026
3. Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an ExampleClinical and Translational Science · 2026
4. QT Myopia and Cardiac Safety: Expanding the Aperture of Arrhythmia Assessment in Early Phase Drug DevelopmentClinical and Translational Science · 2026
5. The RING-Type Ubiquitin Ligase XBAT35.2 Positively Modulates Plant Immunity by Promoting FLS2 Protein AccumulationMolecular Plant-Microbe Interactions · 2026
6. P-1245. An Open-Label Phase 1 Study to Evaluate the Effect of Multiple Doses of Rifabutin on the Single-Dose Pharmacokinetics of Ulonivirine in Adults without HIVOpen Forum Infectious Diseases · 2026
7. Assessment of QT Interval Prolongation Using Concentration-QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals.2025
8. Technical Considerations of Pharmacokinetic Assays for LNP-mRNA Drug Products by RT-qPCRThe AAPS Journal · 2025
9. Long‐acting PYY 3 −36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studiesObesity · 2025
10. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjectsDiabetes Obesity and Metabolism · 2025
11. Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient SafetyClinical and Translational Science · 2025
12. Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult ParticipantsThe Journal of Clinical Pharmacology · 2025
13. Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trialFrontiers in Immunology · 2024
14. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinibClinical and Translational Science · 2024
15. Assessing Product Use Behavior and Exposure: Definitions and MethodsContributions to Tobacco & Nicotine Research · 2024
16. Development of 24-Hour Rhythms in Cortisol Secretion Across Infancy: A Systematic Review and Meta-Analysis of Individual Participant DataThe Journal of Clinical Endocrinology & Metabolism · 2024
17. Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis ForumBioanalysis · 2024
18. A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assaysBioanalysis · 2024
19. The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assaysBioanalysis · 2024
20. Randomized trial of pharmacokinetic and pharmacodynamic effects of 13.2 mg intranasal epinephrine treatment in congestionAnnals of Allergy Asthma & Immunology · 2024